In a prospective study of 32 patients with BPH treated with Minipress
* (prazosin), determinations of drug plasma levels were carried out. The comparison of clinical results and serum plasma levels
enabled optimalization of the dosage in long-term therapy.
Minipress, developed by Pfizer Inc. (USA), was employed.